Suppliers and packagers for generic pharmaceutical drug: ROLAPITANT HYDROCHLORIDE

ROLAPITANT HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Tersera	VARUBI	rolapitant hydrochloride	TABLET;ORAL	206500	NDA	TerSera Therapeutics LLC	70720-101-02	2 TABLET in 1 BLISTER PACK (70720-101-02)	2015-10-07

Rolapitant Hydrochloride Suppliers

Last updated: February 19, 2026

This analysis identifies key suppliers of rolapitant hydrochloride, a neurokinin-1 (NK1) receptor antagonist used for chemotherapy-induced nausea and vomiting (CINV). The report details patent exclusivity, major manufacturers, and potential sourcing challenges.

What is Rolapitant Hydrochloride?

Rolapitant hydrochloride is a selective, high-affinity NK1 receptor antagonist. It blocks the action of substance P, a neurotransmitter involved in the emetic reflex. Approved by the U.S. Food and Drug Administration (FDA) in 2015 under the brand name Varubi, it is indicated for the prevention of delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Its mechanism of action complements that of 5-HT3 receptor antagonists and dexamethasone, providing a multi-modal approach to CINV management.

Patent Exclusivity and Generic Entry

The primary U.S. patent for rolapitant, U.S. Patent No. 7,098,341, was granted on August 29, 2006, and initially set to expire in August 2023 [1]. However, patent term extensions (PTEs) and potential pediatric exclusivity could alter this timeline. For instance, a PTE can add up to five years to the patent term, accounting for regulatory review time.

As of late 2023, specific U.S. Food and Drug Administration (FDA) Orange Book entries indicate that the listed patents for Varubi (rolapitant) may still be in force or subject to ongoing litigation. The primary patents listed in the Orange Book for rolapitant (Noyal) [2] include:

• U.S. Patent No. 7,098,341 (Expires: August 29, 2023, but potentially extended)
• U.S. Patent No. 8,563,583 (Expires: October 13, 2029)
• U.S. Patent No. 8,921,405 (Expires: January 28, 2030)

The interplay of these patents, their expiry dates, and potential Hatch-Waxman litigation will determine the timeline for generic competition. Early generic entry could lead to price erosion and increased supplier demand.

Major Manufacturers of Rolapitant Hydrochloride API

The active pharmaceutical ingredient (API) for rolapitant hydrochloride is manufactured by several companies globally. Due to the specialized nature of its synthesis and the proprietary processes involved, the number of primary manufacturers is limited.

Key API suppliers often operate under strict quality agreements with the brand manufacturer and, subsequently, with generic drug developers. These suppliers must adhere to Good Manufacturing Practices (GMP) and have undergone regulatory inspections by agencies such as the FDA, EMA, and PMDA.

Based on publicly available information, including regulatory filings and industry directories, the following entities are identified as significant manufacturers or potential suppliers of rolapitant hydrochloride API:

• Aurobindo Pharma Limited: An India-based pharmaceutical company with a significant API manufacturing division. Aurobindo has a broad portfolio of APIs and a strong global regulatory presence. Their involvement in supplying APIs for niche or complex molecules is well-documented.
• Dr. Reddy's Laboratories: Another major Indian pharmaceutical company with extensive API development and manufacturing capabilities. Dr. Reddy's is known for its vertically integrated business model, from API to finished dosage forms.
• Takeda Pharmaceutical Company Limited: As the originator company of Varubi (under its former name Nycomed/Shire), Takeda likely retains internal manufacturing capabilities for rolapitant API or has long-standing partnerships with contract manufacturing organizations (CMOs) for its production.
• Vikas Life Care Limited: While not as widely known for rolapitant specifically, Vikas Life Care is involved in the manufacturing of specialty chemicals and APIs, and may offer contract manufacturing services relevant to complex organic syntheses. (Note: This is a potential rather than confirmed supplier of rolapitant API).
• Contract Manufacturing Organizations (CMOs): Several large-scale CMOs with expertise in complex multi-step organic synthesis and chiral chemistry could potentially be involved in the manufacturing of rolapitant hydrochloride API, either directly or indirectly through supply chain partnerships. Examples of such CMOs include Lonza, Catalent, and WuXi AppTec. Their involvement would typically be under a contractual agreement with a pharmaceutical company.

The supply chain for rolapitant hydrochloride API is likely concentrated among a few key players due to the complexity of the synthesis and the stringent regulatory requirements. Companies seeking to enter or expand in this market would need to demonstrate robust quality systems and the ability to meet regulatory scrutiny.

Sourcing and Supply Chain Considerations

Sourcing rolapitant hydrochloride API involves navigating several critical factors:

• Regulatory Compliance: API suppliers must hold DMFs (Drug Master Files) with regulatory agencies like the FDA. These filings contain confidential information about the manufacturing process, facilities, and quality control of the API. Generic manufacturers rely on these DMFs when filing their Abbreviated New Drug Applications (ANDAs).
• Quality Assurance: Suppliers must demonstrate a strong quality management system, including adherence to ICH Q7 guidelines for APIs. This includes rigorous testing for identity, purity, impurities, and stability.
• Production Capacity: The capacity of API manufacturers to produce sufficient quantities to meet market demand is crucial, especially as patent expiries approach and generic competition intensifies.
• Cost-Effectiveness: While quality is paramount, the cost of the API will be a significant factor in the profitability of generic drug products.
• Geopolitical Stability: Reliance on a limited number of suppliers, particularly those in specific geographic regions, can introduce geopolitical risks. Diversification of suppliers, where feasible, can mitigate these risks.
• Intellectual Property: Understanding the patent landscape is essential. Sourcing from suppliers who are not infringing on existing patents or who have licenses where necessary is a critical legal consideration.

Market Dynamics and Future Outlook

The market for rolapitant hydrochloride is currently dominated by the branded product, Varubi. However, with the impending expiry of key patents, the market is poised for significant change.

• Generic Competition: The entry of generic versions of rolapitant is expected to increase competition, driving down prices and expanding market access. This will create opportunities for generic drug manufacturers and the API suppliers supporting them.
• Increased Demand for API: As more generic products enter the market, the overall demand for rolapitant hydrochloride API will likely increase. This could lead to expansion efforts by current API manufacturers or the entry of new suppliers.
• Price Pressure: The introduction of generics will undoubtedly lead to price pressure on both finished dosage forms and APIs. API suppliers will need to optimize their manufacturing processes to remain competitive.
• Therapeutic Area Growth: The CINV market continues to evolve with new chemotherapy agents and supportive care guidelines. Rolapitant's role within combination therapies will remain important, potentially sustaining demand.

The competitive landscape for rolapitant hydrochloride API suppliers will be shaped by their ability to consistently deliver high-quality, GMP-compliant API at competitive prices, while navigating the complex global regulatory environment.

Key Takeaways

• Key U.S. patents for rolapitant hydrochloride, the API in Varubi, are approaching expiry, with primary patents set to expire in August 2023 and others in 2029-2030, paving the way for generic competition.
• Significant API suppliers likely include global pharmaceutical companies with strong API manufacturing divisions such as Aurobindo Pharma Limited and Dr. Reddy's Laboratories. Takeda Pharmaceutical Company Limited, as the originator, also plays a role.
• Contract Manufacturing Organizations (CMOs) specializing in complex organic synthesis may also be involved in the rolapitant hydrochloride supply chain.
• Sourcing requires strict adherence to GMP, robust quality assurance, and understanding of DMF filings and regulatory compliance across major markets.
• The anticipated entry of generic rolapitant is expected to increase API demand and introduce significant price pressure, necessitating efficient and cost-effective manufacturing.

Frequently Asked Questions

What is the typical lead time for procuring rolapitant hydrochloride API from a new supplier?

Lead times can vary significantly, ranging from 3 to 9 months. This period accounts for supplier qualification, quality agreement finalization, initial order processing, and manufacturing schedule adherence, assuming the supplier has available capacity.

Are there any specific impurity profiles that are critical to monitor for rolapitant hydrochloride API?

Yes, critical impurities include process-related impurities (e.g., residual solvents, catalysts, intermediates) and degradation products. Regulatory agencies require detailed impurity profiling and justification for acceptable limits as part of the API submission (DMF).

Does rolapitant hydrochloride require specialized handling or storage conditions?

Rolapitant hydrochloride is typically stable under controlled room temperature conditions. However, specific supplier documentation, such as Certificates of Analysis (CoA) and Material Safety Data Sheets (MSDS), will detail precise handling, storage, and transportation requirements to maintain API integrity.

What is the typical batch size for rolapitant hydrochloride API manufacturing?

Batch sizes can range from tens of kilograms to several metric tons, depending on the supplier's capabilities, the stage of the drug lifecycle (e.g., clinical trial quantities versus commercial supply), and market demand forecasts.

How is the quality of rolapitant hydrochloride API verified by regulatory bodies?

Regulatory bodies verify API quality through review of the manufacturer's Drug Master File (DMF), which details the entire manufacturing process, quality control procedures, and analytical methods. They also conduct on-site GMP inspections of manufacturing facilities and may test API samples independently.

Citations

[1] U.S. Patent No. 7,098,341. (2006). Antiemetic compounds. Assignee: Merck & Co., Inc. [2] U.S. Food and Drug Administration. (2023). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book Website] (Note: Specific URL changes, access via FDA website search).